Sai Life Sciences Ltd
SAILIFE NSE
Sai Life Sciences Ltd
HealthcareNSE: SAILIFE BSE: 544306 Pharmaceuticals & Biotechnology
Key Fundamentals
SmallcapPharmaceuticalsHealthcareMarket Cap
₹30,651 Cr
Volatility
Moderate
P/E Ratio
84.12
EBITDA
₹623 Cr
Return on Equity
7.99%
Debt to Equity
0.12
Book Value
₹116.99
52W High
₹1,475
52W Low
₹783.85
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Sai Life Sciences Ltd insights
39 extracted metrics + investor summaries across FY19–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
1- Company has delivered good profit growth of 42.2% CAGR over last 5 years
Weaknesses
4- Stock is trading at 12.1 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.7% over last 3 years.
- Working capital days have increased from 51.8 days to 77.6 days
Growth Rate
Revenue Growth
26.64% ↗
Net Income Growth
122.10% ↗
Cash Flow Change
19.37% ↗
ROE
-5.89% ↗
ROCE
-1.49% ↗
EBITDA Margin (Avg.)
8.81% ↗
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 20h agoAI opinion · based on fundamentals
Risk high
Sai Life Sciences is a healthcare CDMO trading at a market cap of ₹30,674 Cr with a PE of 85.1x. The company has delivered strong profit growth of 42% CAGR over 5 years and 18% TTM sales growth, but trades at elevated valuations of 12.4x book value with zero dividend payout and deteriorating working capital efficiency.
Bull Case 7
- Compounded profit growth of 42% CAGR over 5 years demonstrates strong earnings momentum and scalability of the CDMO business model
- TTM profit growth of 51% indicates accelerating earnings trajectory in the most recent period
- Compounded sales growth of 24% CAGR over 5 years reflects consistent revenue expansion and growing client base
- 3-year compounded sales growth of 22% shows sustained demand for contract development and manufacturing services
- ROE improved from 9% (5-year average) to 15% in the last year, suggesting improving capital efficiency and margin expansion
- Stock has delivered 63% returns over 1 year, reflecting strong market confidence in the company's growth trajectory
- 3-year compounded profit growth of 226% indicates a sharp inflection point in profitability from a lower base, with operating leverage kicking in
Bear Case 8
- PE ratio of 85.1x is significantly elevated relative to broader market and most healthcare peers, leaving limited margin of safety
- Price-to-book ratio of 12.4x indicates the stock is trading at a steep premium to its net asset value
- Zero dividend yield despite repeated profitability suggests no capital return to shareholders
- 3-year average ROE of only 12.7% is modest for a company commanding such premium valuations
- Working capital days have increased from 51.8 days to 77.6 days, a 50% deterioration indicating potential cash conversion challenges
- 5-year average ROE of just 9% suggests historically weak returns on shareholder equity relative to the capital deployed
- At 85.1x PE, even a slight slowdown from the 51% TTM profit growth could trigger significant multiple compression
- TTM sales growth of 18% has decelerated from the 5-year CAGR of 24%, indicating potential growth moderation
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 20h ago Positives 1
- Q1FY27 profit up 22% YoY Aug 6
Standalone net profit rose 22% YoY to ₹713.39 million for Q1FY27, driven by higher revenue and lower finance costs.
Neutral 2
- Investor meetings in Singapore Aug 4
Sai Life Sciences scheduled analyst and investor meetings for August 13-14, 2026, in Singapore at the Avendus Spark INDX-Asia Edition 2026 event.
- Q1FY27 earnings call scheduled Jul 30
Company to host Q1FY27 earnings call on August 7, 2026, to discuss unaudited financial results for the quarter ended June 30, 2026.
TL;DR: Sai Life Sciences delivered solid Q1FY27 earnings with 22% profit growth, supported by revenue expansion and reduced finance costs. No material headwinds emerged in the recent news flow. The company is actively engaging institutional investors in Asia, signaling confidence. The trend is positive with earnings momentum intact heading into FY27.
Quarterly Results
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 384 | 439 | 280 | 396 | 440 | 580 | 496 | 537 | 556 | 602 | 554 |
| Expenses | 287 | 315 | 254 | 293 | 320 | 422 | 375 | 392 | 369 | 426 | 406 |
| Operating Profit | 96 | 125 | 26 | 102 | 120 | 158 | 121 | 146 | 188 | 177 | 148 |
| OPM % | 25% | 28% | 9% | 26% | 27% | 27% | 24% | 27% | 34% | 29% | 27% |
| Other Income | 11 | 3 | 8 | 10 | 9 | 10 | 10 | 15 | 0 | 16 | 4 |
| Interest | 23 | 21 | 21 | 21 | 23 | 11 | 12 | 9 | 10 | 8 | 8 |
| Depreciation | 31 | 31 | 31 | 36 | 34 | 37 | 38 | 40 | 44 | 45 | 46 |
| PBT | 53 | 76 | -18 | 55 | 72 | 119 | 81 | 112 | 134 | 139 | 98 |
| Tax % | 25% | 26% | -25% | 25% | 25% | 26% | 25% | 25% | 25% | 25% | 25% |
| Net Profit | 40 | 56 | -14 | 42 | 54 | 88 | 60 | 84 | 100 | 104 | 73 |
| EPS in Rs | — | — | — | — | 2.59 | 4.24 | 2.9 | 4 | 4.75 | 4.92 | 3.45 |
Profit & Loss
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 695 | 726 | 760 | 870 | 1,217 | 1,465 | 1,695 | 2,192 | 2,250 |
| Expenses | 520 | 558 | 593 | 743 | 1,048 | 1,178 | 1,285 | 1,561 | 1,592 |
| Operating Profit | 176 | 168 | 167 | 126 | 169 | 287 | 410 | 631 | 658 |
| OPM % | 25% | 23% | 22% | 15% | 14% | 20% | 24% | 29% | 29% |
| Other Income | 6 | 18 | 27 | 28 | 27 | 29 | 35 | 41 | 35 |
| Interest | 24 | 22 | 33 | 54 | 81 | 88 | 78 | 39 | 35 |
| Depreciation | 44 | 55 | 80 | 90 | 99 | 119 | 139 | 167 | 175 |
| PBT | 113 | 109 | 82 | 10 | 16 | 109 | 228 | 466 | 483 |
| Tax % | 35% | 30% | 25% | 36% | 39% | 24% | 25% | 25% | — |
| Net Profit | 73 | 76 | 61 | 6 | 10 | 83 | 170 | 349 | 362 |
| EPS in Rs | — | — | — | — | — | — | 8.16 | 16.48 | 17.12 |
| Div. Payout % | 0% | 0% | 0% | 1117% | 676% | 0% | 0% | 0% | — |
Balance Sheet
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 17 | 18 | 18 | 18 | 21 | 21 |
| Reserves | 703 | 778 | 845 | 861 | 870 | 957 | 2,108 | 2,463 |
| Borrowings | 249 | 304 | 637 | 752 | 933 | 928 | 352 | 288 |
| Other Liabilities | 247 | 312 | 318 | 527 | 358 | 359 | 665 | 854 |
| Total Liabilities | 1,215 | 1,410 | 1,817 | 2,157 | 2,179 | 2,262 | 3,146 | 3,626 |
| Fixed Assets | 373 | 641 | 701 | 751 | 1,037 | 1,180 | 1,488 | 1,815 |
| CWIP | 116 | 91 | 246 | 410 | 151 | 107 | 124 | 270 |
| Investments | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 50 |
| Other Assets | 726 | 679 | 870 | 997 | 989 | 973 | 1,531 | 1,490 |
| Total Assets | 1,215 | 1,410 | 1,817 | 2,157 | 2,179 | 2,262 | 3,146 | 3,626 |
Cash Flow
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating | 129 | 116 | -36 | 105 | 219 | 263 | 314 | 509 |
| Investing | -158 | -262 | -260 | -102 | -99 | -191 | -536 | -395 |
| Financing | 268 | -4 | 296 | 72 | -201 | -95 | 301 | -124 |
| Net Cash Flow | 239 | -150 | -1 | 75 | -80 | -24 | 79 | -10 |
| Free Cash Flow | -28 | -157 | -298 | -102 | 148 | 82 | -55 | -83 |
| CFO/OP | 90 | 81 | -13 | 90 | 132 | 96 | 82 | 87 |
Ratios
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 123 | 136 | 99 | 102 | 85 | 64 | 76 | 62 |
| Inventory Days | 86 | 79 | 127 | 179 | 121 | 72 | 93 | 97 |
| Days Payable | 207 | 258 | 230 | 279 | 180 | 113 | 253 | 182 |
| Cash Conversion Cycle | 1 | -43 | -4 | 2 | 25 | 22 | -83 | -24 |
| Working Capital Days | 55 | 24 | 62 | 42 | 36 | 12 | 66 | 78 |
| ROCE % | — | 13% | 9% | 3% | 6% | 11% | 14% | 20% |
Documents
1
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
15h - Earnings conference call invite for the quarter and year ended Financial Results ended on 31 March, 2026 15h - Earnings conference call invite for the quarter and year ended Financial Results ended on 31 March, 2026
2
Announcement under Regulation 30 (LODR)-Press Release / Media Release
10h - Sai Life Sciences' Bidar campus achieved 100% renewable electricity on 11 May 2026; 97% direct solar/wind, 35,110 tCO₂ saved. 10h - Sai Life Sciences' Bidar campus achieved 100% renewable electricity on 11 May 2026; 97% direct solar/wind, 35,110 tCO₂ saved.
3
Intimation Of An Order Dated 29Th April 2026 Issued By The Joint Commissioner Of Commercial Taxes (Appeals), Kalaburagi U/S 107 (11) Of The Central Goods And Services Tax Act, 2017 And The Karnataka Goods And Services Tax Act, 2017.
30 Apr - Karnataka GST appeals order demands ₹16.28 crore tax, ₹13.32 crore interest, ₹3.26 crore penalty. 30 Apr - Karnataka GST appeals order demands ₹16.28 crore tax, ₹13.32 crore interest, ₹3.26 crore penalty.
4
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
23 Apr - Allotment of 2,44,281 Equity Shares under ESOP Schemes of the Company. 23 Apr - Allotment of 2,44,281 Equity Shares under ESOP Schemes of the Company.
5
Intimation Of An Order Dated 29Th April 2026 Issued By The Joint Commissioner Of Commercial Taxes (Appeals), Kalaburagi U/S 107 (11) Of The Central Goods And Services Tax Act, 2017 And The Karnataka Goods And Services Tax Act, 2017.
30 Apr - Karnataka GST appeals order demands ₹16.28 crore tax, ₹13.32 crore interest, ₹3.26 crore penalty. 30 Apr - Karnataka GST appeals order demands ₹16.28 crore tax, ₹13.32 crore interest, ₹3.26 crore penalty.
Frequently Asked Questions about Sai Life Sciences Ltd
What does Sai Life Sciences Ltd do?
Incorporated in 1999, Sai Life Sciences
Ltd carries out contract research and manufacturing activities for customers
engaged in pharmaceutical and bio
technology industries[1]
Where is Sai Life Sciences Ltd (SAILIFE) listed?
Sai Life Sciences Ltd is listed on the Indian stock exchanges. It is listed on NSE: SAILIFE and BSE: 544306. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Sai Life Sciences Ltd belong to?
Sai Life Sciences Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Sai Life Sciences Ltd?
Sai Life Sciences Ltd has a market capitalisation of approximately ₹30650.69 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Sai Life Sciences Ltd?
The Price-to-Earnings (PE) ratio of Sai Life Sciences Ltd is 84.12. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Sai Life Sciences Ltd?
Over the past 52 weeks, Sai Life Sciences Ltd has traded between a low of ₹783.85 and a high of ₹1,475. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Sai Life Sciences Ltd?
Sai Life Sciences Ltd has a Return on Equity (ROE) of 7.99%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Sai Life Sciences Ltd on Tapetide?
On Tapetide, you can view Sai Life Sciences Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 1999, Sai Life Sciences Ltd carries out contract research and manufacturing activities for customers engaged in pharmaceutical and bio technology industries[1]